In-vitro Bioequivalence (IVBE)

Off-the-shelf devices available for key identified nasal drugs

Accelerate your sprint to market with our Device Equivalence Program

Based on FDA requirements, we have established a Device Equivalence Program in order to accelerate time-to-market and achieve in-vitro bioequivalence requirements.
Our main objective is to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development programs.

Video placeholder To watch this video you must consent the use of cookies.
In-vitro BioEquivalence for nasal spray-Actuator-ENT
In-vitro BioEquivalence for nasal spray-Pump-ENT

Webinar 2020

"Key insights for a successful device development to achieve bioequivalence requirements"

Discover our webinar

Related products


SP270+ and SP370+

SP270+ and SP370+ are our versatile pumps for both Rx/ OTC drug products and medical devices for ear, nose and throat sprays.

Discover More